FDA Hopes To Balance Upfront Time Investment With Easier Reviews In New PMA Program

CDRH Director Jeffrey Shuren hopes that the early, concentrated collaboration that his staff will engage in with manufacturers for select “Expedited Access PMA” devices will make the reviews themselves substantially quicker and easier, he said in an interview.

More from Regulation

More from Policy & Regulation